secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celularity Inc (CELU)
CIK:        0001752828
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0001493152-24-042525
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celularity expects H1 2024 biomaterial revenue >$24M, Rebound >$9M; reaffirms $50-56M FY guidance
--------------------------------------------------------------------------------

- Preliminary net revenue from biomaterial products exceeds $24M for six months ended June 30, 2024, surpassing full-year 2023 sales.
- Acquired Rebound allograft matrix from Sequence LifeScience; generated >$9M in net revenue to date, reimbursed via HCPCS Q4296.
- Reaffirms FY 2024 combined net sales guidance of $50-56M for biomaterial and biobanking businesses.
- Plans to file Q2 2024 10-Q in coming weeks; working to regain Nasdaq listing compliance.
- Product pipeline: Celularity Tendon Wrap 510(k) submission expected early 2025, FUSE Bone Void Filler H2 2025, Placental Matrix 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1752828/000149315224042525/0001493152-24-042525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1752828/000149315224042525/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer